A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies
Nigel Temperton(Medway School of Pharmacy), Robin A. Weiss(Institute of Cancer Research), Yasuhiro Takeuchi(Okinaka Memorial Adult Disease Research Institute), Carolyn Nicolson(National Institute for Biological Standards and Control), Maria Zambon(Public Health England), Do Quang Ha(Oxford University Clinical Research Unit), Menno D. de Jong(National Institute for Public Health and the Environment), Vo Minh Hien(Hospital for Tropical Diseases), R. J. Manvell(Veterinary Medicines Directorate), Diane Major(National Institute for Biological Standards and Control), Katja Höschler(National Security Agency)
Cited by 148
Related Papers
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia
|Nature Medicine|2006|1.9k
A minimal common outcome measure set for COVID-19 clinical research
|The Lancet Infectious Diseases|2020|1.8k
Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
|Journal of Virology|2013|1.3k
SARS-CoV-2 evolution during treatment of chronic infection
|Nature|2021|1.1k